Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior nonsteroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET). / Jerusalem, G. ... [et al.]. Onkológia Roč. 11, č. 4 (2016), s. 250-251